Deal Trends In Alzheimer’s Show Promise
This article was originally published in Start Up
Executive Summary
In the wake of new funding earmarked for Alzheimer’s disease research, START-UP takes a 10-year look at Alzheimer’s dealmaking in Elsevier’s Strategic Transactions.
You may also be interested in...
Alzheimer’s Research To Be More Collaborative, Better Funded Under National Plan
Most of the additional money will help support two trials – one for insulin as a treatment and one for crenezumab as a preventative. The Obama administration formally launched its national Alzheimer’s plan in the midst of a two-day meeting that underscored how little researchers know about the disease.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.